Dexcom (DXCM): The Diabetes Stock Wall Street Ignores

2026-07-03 · By Lubin Danilo, founder of Lubin Investment

Dexcom makes the sensors that track glucose continuously for millions of people with diabetes, no finger prick needed. In my screener, the company checks every one of the ten quality boxes I look for, a rare result. Its current stock price looks reasonable for a business this solid. Here is why, and where the risks sit.

• Dexcom makes the continuous glucose monitor (CGM) sensor worn by millions of people with diabetes, an alternative to finger pricking.
• In my screening grid, Dexcom checks every one of the ten quality criteria I track, a result I see rarely.
• Its free cash flow margin reaches 26.2% and its cash return on capital employed (Cash ROCE) tops 37%.
• The stock currently trades at 22.3 times its annual free cash flow, a level my tool flags as an opportunity.
• The real risk is not in the numbers: it is competition from Abbott and dependence on US health insurance reimbursement.

A sensor you never notice, unless you need one

The first time I saw a Dexcom sensor, it was on the arm of a friend with type 1 diabetes, a small white disc about the size of a two euro coin. He no longer had to prick his finger ten times a day to check his blood sugar. The sensor tracks his glucose continuously, minute by minute, and sends the reading straight to his phone.

That is called a CGM, short for continuous glucose monitoring. Dexcom is one of only two manufacturers that really matter worldwide, alongside Abbott. On my site, DXCM had never appeared as a standalone piece before, it only showed up buried in ranking tables for the Medical Devices sector. That bothered me. A company that keeps landing near the top of every ranking deserves a proper look.

How I judge a stock, before we even get to Dexcom

I always separate two questions most investors blur together. First: is this a good business? Second, completely independent: is now a good price? A great business bought too expensive is still a bad investment. A cheap price on a mediocre business is still a mediocre business.

To answer the first question, I built a checklist of ten objective financial criteria: profitability, sales growth, cash growth, buybacks versus dilution, margins, debt and capital returns. Each stock gets a score out of 10. Only once that score is set do I look at price, separately, with a different tool.

A perfect score, a result I rarely see

Dexcom scores 10 out of 10. All ten criteria pass, and my tool flags zero weak points, not even a minor caveat. After running this screener across thousands of companies for years, a report card this clean without a single reservation is the exception, not the rule. That does not mean Dexcom is flawless, no company is. It means that at the moment I looked, none of my ten financial filters detected a weakness.

Three numbers explain why. First, the free cash flow margin, free cash flow being the cash actually left in the bank once every bill and every investment is paid, sits at 26.2%. Out of every 100 dollars of revenue collected, 26 dollars end up as real cash on hand, not just an accounting profit that can be dressed up. Second, Cash ROCE, the cash return the company earns on every dollar invested in the business, reaches 37.5%. Every dollar Dexcom plows back into factories or research earns 37.5 cents of cash back each year, a level only a handful of companies hit. Third, growth: revenue has grown roughly 17.8% a year on average over five years, riding a global diabetes market that keeps expanding. Despite that fast growth, net debt is only 0.14 times annual free cash flow, meaning Dexcom could pay off all its debt with barely two months of cash generation. Net margin, what is left after absolutely every expense, stands at 19.3%, solid for a company still investing heavily in growth.

Dexcom's real treasure: its moat

Numbers describe the result, not the cause. What protects Dexcom is its moat, its defensive trench against competitors. It rests on three things.

First, the regulatory wall. In 2018, Dexcom's G6 became the first sensor the FDA classified as an iCGM, a category created specifically because the device was reliable enough to drive an insulin pump automatically without human input. Getting that kind of clearance takes years of clinical trials. It is not software a rival can clone in six months.

Second, patient switching costs. A diabetic who has tuned their alerts, calibrated their habits and linked their sensor to their insulin pump does not switch systems on a whim. The Dexcom G7, now worn for fifteen days instead of ten in its latest version, plugs directly into the Tandem t:slim X2, Tandem Mobi, Omnipod 5 and Beta Bionics iLet pumps. Switching sensors often means switching pumps, apps, and clinical routines with a doctor. That friction retains patients far better than any contract could.

Third, the ecosystem. Dexcom does not just sell a sensor, it orchestrates a system that talks to the insulin pump, the patient's app, the doctor's chart. That multi-device integration, built over years, is what makes the position hard to dislodge, far more than any single technical edge on the sensor itself.

Management: a decade of organic growth, a handover underway

Under Kevin Sayer, who became CEO in 2015, Dexcom's revenue grew tenfold, from $402 million to just over $4 billion in 2024. Sayer consistently refused to chase growth through costly acquisitions, choosing instead to reinvest in research and manufacturing. He summed it up himself: Dexcom had been the organic growth story of the decade.

Since January 1, 2026, day-to-day leadership has passed to Jake Leach, the former chief operating officer who knows the company from the inside. Sayer stays on as executive chairman of the board. A CEO transition always deserves watching, but this one is happening internally, with no announced break in strategy, which limits short-term execution risk.

Quality and price are two different things

A perfect score says nothing about what you should pay today. That is where P/FCF comes in, price to free cash flow, the stock price divided by the free cash flow generated each year. A P/FCF of 20 means you are paying today for twenty years of that cash at the current pace. The lower the number, the cheaper the stock is relative to the quality it delivers.

Dexcom currently trades at a valuation of 22.3 times its free cash flow, with the stock at $72.88 and a market capitalization of roughly $28.1 billion. For a company growing close to 18% a year, with this level of profitability and almost no debt, my tool flags this price level as an opportunity at the current share price, not as an obvious steal nor as an overpriced bet. It sits in the middle ground: not cheap enough to look suspicious, not expensive enough to demand flawless execution forever.

The real debate: Abbott, pricing, and reimbursement

Nobody holds a monopoly here. The main rival, Abbott, sells its FreeStyle Libre 3 noticeably cheaper than Dexcom's G7 without insurance, and reads glucose every minute versus every five minutes for Dexcom. On raw accuracy, Dexcom keeps a slight clinical edge, but Abbott is gaining ground on price and simplicity, especially among patients who do not need real-time alerts.

Here is how the two systems compare today in the US market, where both companies generate most of their sales. MARD (the average gap between the sensor's reading and the true blood value; the lower the number, the more accurate the sensor) still slightly favors Dexcom, but Abbott counters with an unbeatable price and more frequent readings.

The second risk is dependence on US health insurance. A meaningful share of Dexcom's revenue relies on Medicare and private insurers reimbursing the sensor. An unfavorable shift in those rules, or a balance of power tilting toward payers, would hit margins directly.

The third risk is product execution. Dexcom just extended the G7's wear time to fifteen days from ten, and is pushing Stelo, an over-the-counter sensor for people without diabetes or with prediabetes who just want to track their glucose out of curiosity or for wellness. That is a genuine potential growth lever, provided mainstream demand actually shows up at scale, which remains unproven.

How I call it

On quality, Dexcom checks every box I test for, without exception, a result I rarely see even among very good companies. On price, the current level of 22.3 times free cash flow looks justified by the growth and profitability on offer, without being a clearance sale. The real question, as always, is not whether Dexcom is a good business, the answer is clearly yes, it is how much you are willing to pay to own it, and whether that matches your own margin of safety.

I built my analysis tool precisely to answer that two-part question, quality then price, in seconds for any stock, without wading through a two-hundred-page annual report. You can see the full ten-criteria breakdown and my fair buy price for Dexcom on the Dexcom analysis page, or read how I build this checklist on my methodology page.

FAQ

What exactly is a CGM?

A CGM (continuous glucose monitoring) is a small sensor worn on the skin that measures blood sugar every few minutes, with no finger pricks, and sends the data to a phone or an insulin pump.

Why give a stock a perfect 10 out of 10 if price matters too?

Because the quality score and the price answer two different questions. A 10 out of 10 means the business is solid across every financial criterion I check (profitability, growth, debt, capital returns). It says nothing about what to pay for it, which is why I look at P/FCF separately.

Is Abbott a serious threat to Dexcom?

Yes, it is a real and serious competitor, cheaper and with more frequent readings. But patient switching costs and Dexcom's integration with insulin pumps limit how fast that threat can bite in the short term.

Is a P/FCF of 22 times expensive?

It depends on the growth and quality behind it. For a company growing 18% a year with very little debt, my tool treats this level as an opportunity, not a red flag. A P/FCF ratio never means anything on its own, outside the context of quality.

Voir l'analyse DXCM sur Lubin Investment

About the author

Written by Lubin Danilo, founder of Lubin Investment. A self-taught individual investor, I find fundamental analysis fascinating, and it has delivered excellent results. For three years now, my performance has beaten the S&P 500. But analyzing every stock took too much time: sites with incomplete data, calculation methods and criteria never aligned with mine. And spotting the best stocks was just as time-consuming, even with my own well-defined checklist. So I put my software development background to work to build this software, base my investment strategy on its results, and share it with people who share the same passion as me. It judges a company's quality and its price separately, using criteria drawn from the financial literature (Warren Buffett, Michael Mauboussin, Aswath Damodaran).